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Introduction
The HIV-1 pandemic continues to expand while no
effective vaccine is yet available. Finding new therapeutic
t a r g e t sa n dd r u g si st h e r e f o r ec r u c i a l .W eh a v ep r e -
viously shown that the dendritic cell immunoreceptor
(DCIR), a C-type lectin receptor expressed in dendritic
cells (DCs), acts as an attachment factor for HIV-1 to
DCs and contributes to HIV-1 transmission to CD4+ T
lymphocytes (CD4TL). Directly involved in HIV-1 infec-
tion, DCIR is expressed in apoptotic or infected CD4TL
and promotes trans-infection to bystander cells. The
aim of the present study is to characterize the extracel-
lular domain of DCIR and to test chemical inhibitors of
HIV-1 attachment thereto.
Results
We present the first three-dimensional model of DCIR
structure. Based on this structure, several inhibitors
were selected to target viral interaction with the car-
bohydrate recognition domain and the EPS motif. Pre-
liminary screening using Raji-CD4-DCIR cells
identified two inhibitors that decreased HIV-1 attach-
ment and propagation. These inhibitors did not affect
the proliferation of peripheral blood mononuclear
cells.
Conclusions
The results of this study thus suggest structures for
novel molecules capable of blocking HIV-1 transmission
by DCs and CD4TL.
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